ConvaTec ( (GB:CTEC) ) has issued an announcement.
Convatec reported strong financial results for 2024, with a 6.9% increase in revenue to $2.289 billion and a 23.7% rise in operating profit to $325 million. The company achieved double-digit growth in adjusted EPS and cash flow, driven by its FISBE strategy and successful product launches. Convatec is confident in its 2025 outlook, expecting continued organic growth and improvements in operating margins, supported by its innovative product pipeline and strategic focus on high-growth market segments.
More about ConvaTec
Convatec is a global medical products and technologies company specializing in solutions for managing chronic conditions. It holds leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care, operating in around 90 countries with over 10,000 employees. The company’s products focus on infection prevention, skin protection, and improving patient outcomes, contributing to reduced care costs. Convatec is part of the FTSE 100 Index.
YTD Price Performance: 11.48%
Average Trading Volume: 4,790,522
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £5.05B
For detailed information about CTEC stock, go to TipRanks’ Stock Analysis page.